Journal of Shanghai Jiao Tong University (Medical Science) >

2026 , Vol. 46 >Issue 5: 585 - 593

DOI: https://doi.org/10.3969/j.issn.1674-8115.2026.05.004

Basic research

Novel approach to hypertrophic scar treatment based on evidence of bacterial overload

  • Yuan Bo ,
  • Yu Jiarong ,
  • Zhang Zheng ,
  • Wang Xiqiao ,
  • Liu Yan ,
  • Xia Zhaofan
Expand
  • 1.Department of Burns, Plastic Surgery and Wound Repair, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2.Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
    3.Department of Burn Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China
Wang Xiqiao, E-mail: wxqiao2002@hotmail.com.

Received date: 2025-11-19

  Accepted date: 2026-01-19

  Online published: 2026-05-28

Supported by

National Natural Science Foundation of China(82472555，82472544);Shanghai Top Priority Research Center Project(2023ZZ02013)

Fold

Abstract

Objective ·To investigate the effects of bacteria on fibroblast function in vitro and the impact of bacterial intervention on hypertrophic scars in rabbit ears in vivo. Methods ·A total of 16 clinical hypertrophic scar specimens and normal skin tissues were collected from patients admitted to the Department of Burns, Plastic Surgery and Wound Repair, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, from January 2023 to December 2024, and subjected to Gram staining. After amplification and inactivation, standard Staphylococcus aureus was used to treat fibroblasts derived from normal skin at concentrations of 102, 103, and 104 CFU/mL. The effects on fibroblast proliferation were observed by using Edu staining, while α-smooth muscle actin (α-SMA) expression was detected by immunofluorescence. The expression levels of vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), type Ⅰ collagen and type Ⅲ collagen were measured by Western blotting. Additionally, the secretion of inflammatory cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1), was evaluated by using enzyme-linked immunosorbent assay (ELISA). In the in vivo study, 80 wounds were created on the ears of 10 New Zealand white rabbits, followed by inoculation with Staphylococcus aureus. After hypertrophic scar formation, intradermal injections of levofloxacin or saline were administered. Scar growth was monitored, and Vancouver Scar Scale scores were recorded. Scar tissues were harvested for hematoxylin and eosin staining, Masson staining, and Gram staining, along with immunohistochemical detection of IL-6, IL-8, TNF-α, and MCP-1 expression. Results ·Clinical scar tissues exhibited significantly greater abundance of Gram-positive bacteria than normal skin tissues (P=0.001). In vitro experiments demonstrated that low-abundance bacteria (102 and 10³ CFU/mL) significantly promoted fibroblast proliferation (P=0.045, P=0.017) and α-SMA expression (P=0.042, P=0.002). These bacteria also enhanced the expression of VEGF (P=0.023, P=0.011), TGF-β1 (P=0.029, P=0.031), type Ⅰ collagen (P=0.032, P=0.025), and type Ⅲ collagen (P=0.019, P=0.027), as well as the secretion of inflammatory cytokines IL-6 (P=0.023, P=0.011), IL-8 (P=0.021, P=0.009), TNF-α (P=0.029, P=0.011), and MCP-1 (P=0.023, P=0.008). In the rabbit ear model, levofloxacin injection significantly reduced scar hyperplasia at 45 and 60 days (P=0.019, P=0.013). At 60 days, treated scars showed decreased inflammatory cell infiltration, reduced bacterial load, less collagen deposition, and lower expressions of IL-6 (P=0.025), IL-8 (P=0.021), MCP-1 (P=0.028), and TNF-α (P=0.019). Conclusions ·Low-abundance bacteria promote the profibrotic capacity of scar fibroblasts, while antibiotic application effectively mitigates hypertrophic scar formation.

Key words： hypertrophic scar; bacteria; fibroblast; inflammatory cytokine

Cite this article

Yuan Bo , Yu Jiarong , Zhang Zheng , Wang Xiqiao , Liu Yan , Xia Zhaofan . Novel approach to hypertrophic scar treatment based on evidence of bacterial overload[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026 , 46(5) : 585 -593 . DOI: 10.3969/j.issn.1674-8115.2026.05.004

References

[1] Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis[J]. Int J Mol Sci, 2017, 18(3): 606.
[2] Caven L T, Carabeo R A. The role of infected epithelial cells in Chlamydia-associated fibrosis[J]. Front Cell Infect Microbiol, 2023, 13: 1208302.
[3] Yang N, Zhang H, Zhang Y H, et al. Bacterial colonization contributes to pathological scar formation via the regulation of inflammatory response[J]. J Transl Med, 2025, 23(1): 569.
[4] Duan X Z, Li J, Gao R Z, et al. Antimicrobial hydrogel loaded with broccoli exosomes promotes anti-scarring healing of MRSA-infected wounds[J]. Mater Today Bio, 2025, 35: 102276.
[5] Yu J R, Mao Z G, Zhou Z D, et al. Microbiome dysbiosis occurred in hypertrophic scars is dominated by S. aureus colonization[J]. Front Immunol, 2023, 14: 1227024.
[6] Hu C H, Tseng Y W, Chiou C Y, et al. Bone marrow concentrate-induced mesenchymal stem cell conditioned medium facilitates wound healing and prevents hypertrophic scar formation in a rabbit ear model[J]. Stem Cell Res Ther, 2019, 10(1): 275.
[7] Laarman A J, Ruyken M, Malone C L, et al. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion[J]. J Immunol, 2011, 186(11): 6445-6453.
[8] Awuh J A, Flo T H. Molecular basis of mycobacterial survival in macrophages[J]. Cell Mol Life Sci, 2017, 74(9): 1625-1648.
[9] Tomlinson K L, Riquelme S A, Baskota S U, et al. Staphylococcus aureus stimulates neutrophil itaconate production that suppresses the oxidative burst[J]. Cell Rep, 2023, 42(2): 112064.
[10] Smith R S, Smith T J, Blieden T M, et al. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation[J]. Am J Pathol, 1997, 151(2): 317-322.
[11] Silzle T, Randolph G J, Kreutz M, et al. The fibroblast: sentinel cell and local immune modulator in tumor tissue[J]. Int J Cancer, 2004, 108(2): 173-180.
[12] Bahcecioglu I H, Koca S S, Poyrazoglu O K, et al. Hepatoprotective effect of infliximab, an anti-TNF-α agent, on carbon tetrachloride-induced hepatic fibrosis[J]. Inflammation, 2008, 31(4): 215-221.
[13] Therrien F J, Agharazii M, Lebel M, et al. Neutralization of tumor necrosis factor-α reduces renal fibrosis and hypertension in rats with renal failure[J]. Am J Nephrol, 2012, 36(2): 151-161.
[14] Papiris S A, Tomos I P, Karakatsani A, et al. High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations[J]. Cytokine, 2018, 102: 168-172.
[15] Wong L, Hutson P R, Bushman W. Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis[J]. Prostate, 2015, 75(1): 23-32.
[16] Yan X, Jiang R H, Tang Q H, et al. Targeting local glucocorticoid metabolism with a silk fibroin microneedle for more effective hypertrophic scar repair[J]. Int J Biol Macromol, 2025, 319(Pt 4): 145753.
[17] Farokh Forghani S, Sobouti B, Shahbazi A, et al. Comparing the efficacy of triamcinolone acetonide versus bleomycin in hypertrophic scars in burn patients: a clinical trial[J]. Med J Islam Repub Iran, 2024, 38: 111.
[18] Sabat R, Jemec G B E, Matusiak ?, et al. Hidradenitis suppurativa[J]. Nat Rev Dis Primers, 2020, 6(1): 18.
[19] Beattie P E, Lewis-Jones M S. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis[J]. Clin Exp Dermatol, 2003, 28(5): 549-553.
[20] Belloni Fortina A, Neri L. Antibiotic therapy in the management of atopic dermatitis[J]. G Ital Dermatol Venereol, 2015, 150(3): 321-325.
Options
Outlines

/

〈 〉